Australian Public Assessment Reports (AusPAR)

AusPAR for Keytruda (pembrolizumab) for the treatment of Oesophageal Cancer

AusPAR for withdrawn Aduhelm (aducanumab) for proposed treatment of Alzheimer’s disease.

AusPAR for Keytruda (pembrolizumab) for the treatment relapsed or refractory classical Hodgkin Lymphoma

AusPAR for Keytruda (pembrolizumab) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumours who are ineligible for or have elected not to undergo cystectomy.

AusPAR for Lumakras (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy for advanced disease.

AusPAR for Opdivo (nivolumab) for the treatment of adjuvant treatment of patients with muscle invasive urothelial carcinoma (MIUC).

AusPAR for Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection and disease resistant, refractory or intolerant to one or more prior therapies

AusPAR for Ultomiris (ravulizumab) for the treatment of paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

AusPAR for Lucentis (ranibizumab) for the treatment of retinopathy of prematurity

AusPAR for Filpegla (pegfilgrastim) for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia.

AusPAR for Prevenar 20 (pneumococcal polysaccharide conjugate vaccine) for the prevention of pneumococcal disease caused by Streptococcus pneumoniae.

AusPAR for Keytruda (pembrolizumab) for the treatment of triple-negative breast cancer.

AusPAR for JAKAVI (ruxolitinib phosphate) for the treatment of graft-versus-host disease.

New AusPAR for Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2.

AusPAR for Verorab (inactivated rabies virus) for pre- and post-exposure prophylaxis against rabies.

AusPAR for ​Exkivity (Mobocertinib) for treatment of patients with locally advanced or metastatic non-small lung cancer.

Ardalicip / Ciptunec (adalimumab) for the treatment of arthritis, crohn's disease, ulcerative colitis, psoriasis, uveitis and acne inversa.

Byooviz (ranibizumab) for the treatment of neovascular age-related macular degeneration etc.

Zyamis midazolam maleate for the treatment of Generalised Convulsive Status Epilepticus (GCSE).

BIMZELX (bimekizumab) for treatment of moderate to severe plaque psoriasis in adult patients .

Trastucip and Tuzucip (trastuzumab) for the treatment of breast cancer and gastric cancer

Scemblix (Asciminib) for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukaemia

Vabysmo (faricimab) for the treatment of neovascular age-related macular degeneration and diabetic macular oedema.

New AusPAR for RYALTRIS - olopatadine and mometasone furoate for allergic rhinitis and rhinoconjunctivitis.

AusPAR for Tecentriq (atezolizumab) for conversion of provisionally registered indication (for treatment of locally advanced or metastatic triple negative breast cancer (mTNBC)) to full registration (withdrawn).